Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

On Wednesday, Johnson & Johnson JNJ reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion.Operational growth was 6.7%, and adjusted operational growth was 5.7%.Raymond James noted that the company’s initial 2025 EPS guidance was slightly better than anticipated, despite facing foreign exchange (FX) challenges. However, the MedTech ...